Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 31, No. 6, 2008
Issue release date: February 2009
Section title: Original Paper
Free Access
Kidney Blood Press Res 2008;31:421–432

A Mutation in the Mouse Chd2 Chromatin Remodeling Enzyme Results in a Complex Renal Phenotype

Marfella C.G.A.a · Henninger N.b · LeBlanc S.E.a · Krishnan N.c · Garlick D.S.d · Holzman L.B.e · Imbalzano A.N.a
Departments of aCell Biology and bNeurology, cRenal Division, Department of Internal Medicine, and dDepartment of Cancer Biology, University of Massachusetts Medical School, Worcester, Mass., and eDivision of Nephrology, University of Michigan Medical School, Ann Arbor, Mich., USA
email Corresponding Author

Anthony N. Imbalzano

Department of Cell Biology, University of Massachusetts Medical School

55 Lake Avenue North, Worcester, MA 01655 (USA)

Tel. +1 508 856 1029, Fax +1 508 856 5612

E-Mail anthony.imbalzano@umassmed.edu

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background and Aims: Glomerular diseases are the third leading cause of kidney failure worldwide, behind only diabetes and hypertension. The molecular mechanisms underlying the cause of glomerular diseases are still largely unknown. The identification and characterization of new molecules associated with glomerular function should provide new insights into understanding the diverse group of glomerular diseases. The Chd2 protein belongs to a family of enzymes involved in ATP-dependent chromatin remodeling, suggesting that it likely functions as an epigenetic regulator of gene expression via the modification of chromatin structure. Methods: In this study, we present a detailed histomorphologic characterization of mice containing a mutation in the chromodomain helicase DNA-binding protein 2 (Chd2). Results: We show that Chd2-mutant mice present with glomerulopathy, proteinuria, and significantly impaired kidney function. Additionally, serum analysis revealed decreased hemoglobin and hematocrit levels in Chd2-mutant mice, suggesting that the glomerulopathy observed in these mice is associated with anemia. Conclusion: Collectively, the data suggest a role for the Chd2 protein in the maintenance of kidney function.

© 2009 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: September 30, 2008
Accepted: November 17, 2008
Published online: January 14, 2009
Issue release date: February 2009

Number of Print Pages: 12
Number of Figures: 5
Number of Tables: 2

ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)

For additional information: http://www.karger.com/KBR

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.